Last reviewed · How we verify
Ischemic Stroke
Approved treatments
- Radicava · Kk Bcj-94
Radicava works by scavenging free radicals and reducing oxidative stress in the body. - 3-Butylphthalide · CSPC Ouyi Pharmaceutical
- Savaysa · Daiichi Sankyo Inc
Savaysa works by blocking the action of coagulation factor X, a key protein involved in blood clotting. - PF-07976016 Formulation A · Pfizer
- Activase · Roche
- Radicava · Shanghai Auzone Biological Technology Co., Ltd.
- Activase · Medical College of Wisconsin
Pipeline
- Antiplatelet Drug · Pfizer Inc. — discontinued
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Ischemic Stroke patent landscape — cliff calendar, originator estates, attackable patents
- Ischemic Stroke treatment landscape brief
- Ischemic Stroke treatment updates RSS
Frequently asked questions about Ischemic Stroke
What drugs treat Ischemic Stroke?
Tracked treatments include Radicava, 3-Butylphthalide, Savaysa, PF-07976016 Formulation A, Activase.
What is the treatment for Ischemic Stroke?
Standard treatment for Ischemic Stroke includes Radicava, 3-Butylphthalide, Savaysa, PF-07976016 Formulation A, Activase. See the treatment landscape page for first-line, second-line and salvage options.
What new drugs are in development for Ischemic Stroke?
1 pipeline drugs tracked. Top candidates: Antiplatelet Drug.
Related
- Treatment landscape: Ischemic Stroke patent cliff · Ischemic Stroke CI report
- Treatment: Radicava · Kk Bcj-94
- Treatment: 3-Butylphthalide · CSPC Ouyi Pharmaceutical
- Treatment: Savaysa · Daiichi Sankyo Inc
- Treatment: PF-07976016 Formulation A · Pfizer
- Treatment: Activase · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing